Skip to search formSkip to main contentSkip to account menu

inogatran

Known as: N-(2-(2-(((3-((aminoiminomethyl)amino)propyl)amino)carbonyl)-1-piperidinyl)-1-(cyclohexylmethyl)-2-oxo-ethyl)glycine 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (3)

AntithrombinsGlycinePiperidines

Narrower (1)

H 314-27
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease.
2003
2003
Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease
Summary Unstable coronary artery disease is in most cases associated with plaque rupture, activation of the coagulation system… 
2001
2001
Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro.
2001
2001
Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease.
AIMS The purpose of this study was to characterize the relationship between the degree of anticoagulation, assessed by APTT, and… 
Review
2001
Review
2001
Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs
Abstract. Small-molecule direct thrombin inhibitors represent a new class of anticoagulants and are emerging as antithrombotic… 
2001
2001
The effects of oral and intravenous direct thrombin inhibitors on the size of photochemically induced cortical infarction in rats.
1999
1999
Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C.
1998
1998
The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin.
The thrombin inhibitors argatroban, efegatran, NAPAP, CH 1091, CH 248, inogatran and melagatran have been characterised with… 
1997
1997
A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition…
BACKGROUND Unstable coronary artery disease, i.e. unstable angina or non-Q wave myocardial infarction, is caused by rupture of… 
1996
1996
Thrombin inhibition with inogatran for unstable angina pectoris: evidence for reactivated ischaemia after cessation of short‐term treatment
BackgroundThe acute coronary syndromes of unstable angina and non-Q-wave infarction are initiated by coronary plaque rupture and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)